Pharmaceuticals, Biotechnology and Life Sciences
Novartis and Pear Therapeutics will develop new treatments for patients with schizophrenia and multiple sclerosis, with Pear’s prescription digital therapeutics…
Alkermes revealed positive results from a phase 4 clinical study of its schizophrenia injectable drug Aristada. Alkermes said on Monday…
The U.S. Food and Drug Administration (FDA) has approved Alkermes’s two-month Aristada (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
Mylan has launched of Perphenazine Tablets USP, a generic version of Schering’s Trilafon Tablets 2 mg, 4 mg, 8 mg and 16 mg.
U.S. Food and Drug Administration (FDA) has accepted Allergan’s supplemental New Drug Application (sNDA) for VRAYLAR (cariprazine), seeking the addition of new clinical data evaluating VRAYLAR for the maintenance of efficacy in adults with schizophrenia to the current product label.
The study, which will be conducted in up to 70 healthy individuals, aims to evaluate the tolerability of KarXT compared to xanomeline alone.
Alkermes plcp has announced that the U.S. Food and Drug Administration (FDA) has approved Aristadatm (aripiprazole lauroxil) extended-release injectable suspension for the treatment of schizophrenia.
The National Institutes of Health has shared its second wave of grants to support the goals of the Brain Research through…
Allergan plc and Gedeon Richter Plc. have announced that the U.S. Food and Drug Administration (FDA) has approved Vraylartm (cariprazine) capsules,…